Use of a three-microRNA signature to discriminate prognostic groups in early-stage NSCLC patients in the IFCT-0002 trial. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This ...
Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results